Myasthenia gravis after allogeneic bone marrow transplantation for lymphoblastic lymphoma

J. E. Dowell, P. L. Moots, R. S. Stein

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


A 31-year-old female with lymphoblastic lymphoma developed myasthenia gravis (MG) 26 months after receiving an allogeneic bone marrow transplant (BMT) from an HLA-identical sister. She presented with classic symptoms and electromyographic evidence of the disorder approximately 2 weeks after electing to abruptly discontinue her immunosuppressive medications. She initially responded to steroids and acetylcholinesterase inhibitors. Her subsequent course has been characterized by episodes of moderately severe weakness that respond to intravenous immunoglobulin and prednisone. This case of post-transplant MG is only the second reported to have occurred in association with BMT for lymphoblastic lymphoma. Potential risk factors for the development of post-transplant MG are discussed including underlying hematological disorder, HLA phenotype, family history of MG, the presence of chronic GVHD, and recent cessation of immune suppression.

Original languageEnglish (US)
Pages (from-to)1359-1361
Number of pages3
JournalBone Marrow Transplantation
Issue number12
StatePublished - 1999


  • Allogeneic bone marrow transplant
  • Graft-versus-host disease
  • Lymphoblastic lymphoma
  • Myasthenia gravis

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Myasthenia gravis after allogeneic bone marrow transplantation for lymphoblastic lymphoma'. Together they form a unique fingerprint.

Cite this